Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

NCT04717635 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Onset Still's Disease

Interventions

BIOLOGICAL: Canakinumab

Sponsor

Novartis Pharmaceuticals